have shown that targeting the Nanog and ERK1/2 signaling pathways can prevent or reverse the CSC phenotype and epithelial-mesenchymal transition that drive tumor progression, metastasis, and radiotherapy resistance in patients with HNSCC (12). The gene discussed is NANOG; the disease is neoplasm.